Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC

Giorgio Scagliotti

At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

Share this video  
Similar topics
Related videos
3:38
Studies on EGFR mutants in NSCLC
Hossein Borghaei
3:39
What is durvalumab’s future as a treatment option in lung cancer?
Luis Paz-Ares
1:23
ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases
Giorgio Scagliotti
1:24
Durvalumab: the new standard of care for NSCLC?
Johan Vansteenkiste
0:56
Pembrolizumab and the significance of PD-L1 for lung cancer
Roy Herbst
Lung Cancer
Docetaxel, Ramucirumab
ECC 2015
Interview
26th September 2015
More from Giorgio Scagliotti
Phase 2 trial of BI 1482694 (HM61713), third-generation TKI, in T790M-positive NSCLC
Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
ASCEND-1 and ASCEND-2: Ceritinib for ALK-rearranged NSCLC and baseline brain metastases
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJOncology is intended for healthcare professionals